Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NMDA Modulation in Late-Life Major Depressive Disorder
NCT03414931Phase 2Completed
- Sponsor
- Chang Gung Memorial Hospital
- Start
- Jan 2016
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sodium benzoate in major depressive disorder (MDD), sponsored by Chang Gung Memorial Hospital. Started Jan 2016; status: completed.
02
Drugs
sodium benzoate
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03414931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03414931.